HC Wainwright Has Positive Outlook for SLGL Q3 Earnings

Sol-Gel Technologies Ltd. (NASDAQ:SLGL) – HC Wainwright boosted their Q3 2026 EPS estimates for shares of Sol-Gel Technologies in a research note issued to investors on Tuesday, October 6th. HC Wainwright analyst R. Selvaraju now forecasts that the company will earn ($1.54) per share for the quarter, up from their previous estimate of ($1.71). HC Wainwright has a “Buy” rating on the stock. The consensus estimate for Sol-Gel Technologies’ current full-year earnings is ($4.95) per share. HC Wainwright also issued estimates for Sol-Gel Technologies’ Q4 2026 earnings at ($1.77) EPS, Q1 2027 earnings at ($1.14) EPS, Q2 2027 earnings at ($1.08) EPS, Q4 2027 earnings at ($1.41) EPS and FY2027 earnings at ($4.92) EPS.

A number of other research analysts also recently weighed in on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Sol-Gel Technologies in a report on Tuesday, September 1st. Mizuho initiated coverage on Sol-Gel Technologies in a research report on Wednesday, June 24th. They issued an “outperform” rating and a $285.00 price target for the company. One equities research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $197.50.

Sol-Gel Technologies Price Performance

SLGL opened at $71.94 on Thursday. The company has a market capitalization of $202.15 million, a PE ratio of -12.76 and a beta of 1.14. The business has a 50-day moving average of $73.58 and a 200-day moving average of $74.35. Sol-Gel Technologies has a fifty-two week low of $28.81 and a fifty-two week high of $97.97.

Sol-Gel Technologies (NASDAQ:SLGL) last posted its quarterly earnings results on Friday, August 21st. The company reported ($1.13) earnings per share for the quarter, topping analysts’ consensus estimates of ($2.36) by $1.23. The business had revenue of $0.59 million for the quarter, compared to the consensus estimate of $0.07 million. Sol-Gel Technologies had a negative net margin of 910.14% and a negative return on equity of 44.05%.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Sol-Gel Technologies stock. Affinity Asset Advisors LLC bought a new position in shares of Sol-Gel Technologies Ltd. (NASDAQ:SLGL) during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 35,000 shares of the company’s stock, valued at approximately $2,773,000. Affinity Asset Advisors LLC owned 1.25% of Sol-Gel Technologies at the end of the most recent quarter. Hedge funds and other institutional investors own 26.18% of the company’s stock.

Insider Activity at Sol-Gel Technologies

In other Sol-Gel Technologies news, major shareholder Opaleye Management Inc. acquired 35,113 shares of the business’s stock in a transaction that occurred on Friday, August 28th. The stock was acquired at an average price of $69.32 per share, with a total value of $2,434,033.16. Following the transaction, the insider owned 520,000 shares of the company’s stock, valued at approximately $36,046,400. This trade represents a 7.24% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders bought 53,659 shares of company stock valued at $3,701,674 in the last 90 days. Insiders own 66.51% of the company’s stock.

About Sol-Gel Technologies

Sol-Gel Technologies Ltd. (NASDAQ: SLGL) is an Israeli specialty pharmaceutical company focused on developing and commercializing topical dermatological treatments. The company uses proprietary silica-based microsponge technology designed to encapsulate and gradually release active pharmaceutical ingredients in the skin.

Its marketed products include TWYNEO, a topical cream combining tretinoin and benzoyl peroxide for the treatment of acne vulgaris, and EPSOLAY, a topical benzoyl peroxide cream for the treatment of inflammatory lesions associated with rosacea.